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To the Editor—Family violence (FV) is an important 
cause of homicide, of which an alarming example 
was a tragic event in Tin Shui Wai. In April 2012, a man 
killed his wife in a hotel and committed suicide by 
leaping. Another homicide-suicide incident in May 
2012 led to two deaths and three injured by a man in 
mental relapse. What is the current situation?
 About 50 homicides are reported annually by 
the Hong Kong Police Force.1 Based on newspaper 
reports presented in a Family Violence Conference 
in 2010 in Tuen Mun Hospital, 165 FV-related 
homicides that occurred from January 1997 to June 
2010 contributed to one quarter of the homicides 
reported by the local police. In all, these entailed 
183 homicide victims (aged 0-84 years), of whom two 
thirds were females and one third were children. 
Notably, 46 assailants committed suicide leading 
to 229 deaths. Stabbing/chopping (31%) was the 
most frequent killing mode and the assailants were 
mainly parents (36%) and spouses (29%). Thus, FV 
is a sizeable public health problem with complex 
family dynamics and conflicts may not be readily 
discernible.2 Identification of risk factors (low 
education level, unemployment, extramarital affairs, 
influence of alcohol, and mental illness) and triggers 
(separation, divorce, child custody, and insults about 
a partner’s earning capacity/sexual ability) could 
serve an important role in prevention.3 Nevertheless, 
certain barriers to danger assessment of local FV 
victims have been described, and include inadequate 
medical staff training, insufficient assessment 
time, and lack of medical social service support.4 
Escalation of FV may end up in death, of which FV-
related homicide is an important indicator. A local 
monitoring system is urgently needed to guide the 
development of the pertinent government policies to 
remedy this situation. 
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To the Editor—In a recent review, Chu1 described 
the importance of biomarkers in the diagnosis of 
Alzheimer’s disease (AD). Indeed there is a paradigm 
change to a biomarker-driven diagnosis of AD 
as reflected by the revised National Institute on 
Aging and Alzheimer’s Association criteria for AD 
published in 2011.2 However, we would like to raise 
several caveats. First, there are various technical 
problems with the existing AD biomarkers,3,4 eg 
poor standardisation and reproducibility across 
laboratories, so that universally agreed standards for 
determining abnormal results are not yet established. 
In addition, multiple brain pathologies frequently 
co-exist in dementia, and AD pathology does not 
necessarily correlate with clinical symptoms, making 
interpretation of the biomarker findings difficult. 
Second, availability and costs of the AD biomarkers 
pose challenges to our public medical services, where 
resources are already overstretched.5 Third, the use of 
AD biomarkers only results in an incremental gain in 
the accuracy of diagnosis by an experienced clinician. 
The AD biomarkers are clearly a scientific advance, 
but further studies on their clinical utility and cost-
effectiveness in the diagnosis of AD are required 
before their widespread clinical use. The scientific 




and more available biomarkers with good sensitivity 
and specificity for the diagnosis. Furthermore, we 
believe that the priority for dementia care in Hong 
Kong is to provide early diagnosis and treatment for 
the rapidly growing number of patients. Policymakers 
should carefully formulate a policy that makes the 
best use of our resources to achieve these goals. 
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Authors’ reply
To the Editor—In my recent review on ‘Alzheimer’s 
disease: early diagnosis and treatment’, I have 
summarised the recent international research 
literature on biomarkers on Alzheimer’s disease 
(AD).1 The purpose of including the biomarkers 
section was to make local readers aware of their 
value. In the 2011 revised recommendations from 
the National Institute on Aging and Alzheimer’s 
Association (NIA-AA) workgroups on diagnostic 
guidelines for Alzheimer’s disease,2 the core criteria 
for AD diagnosis were very similar to the previous 
1984 clinical criteria for probable AD.3 Without any 
biomarker, clinicians can still apply the core criteria 
to make a clinical diagnosis of probable AD. However, 
the addition of biomarkers for AD improves the 
sensitivity and specificity of AD diagnosis. Biomarkers 
are also useful for the differential diagnosis of other 
dementia subtypes or in mixed brain pathologies.1 
An accurate diagnosis of AD could guide the 
subsequent use of current symptomatic treatments 
for AD. The NIA-AA workgroups also recommend 
using biomarkers in research,2 and guidelines on 
using biomarkers of AD are helpful in diagnosing 
mild cognitive impairment due to underlying AD as 
well as in preclinical dementia due to AD.4,5 Certainly, 
the availability of diagnostic resources is still limited 
in Hong Kong. Currently, brain magnetic resonance 
imaging is available in most local hospitals and a 
semi-quantitative rating can be done.1 The most 
expensive Pittsburgh compound B–positron emission 
tomographic brain scan is only available in one local 
private hospital. Cerebrospinal fluid biomarkers 
assays are still under development in some hospitals. 
Similar to other laboratory procedures, local 
laboratory standardisation and establishment of local 
reference values are important for all biomarkers, 
whether in Hong Kong or elsewhere. Future local 
research studies to confirm the validity of these 
biomarkers are recommended. 
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